Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry by Barbara Kind, Luise Heinrich, Thomas Werfel, Jochen Schmitt, Stephan Weidinger

Get full text

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE by Jonathan I. Silverberg, Eric L. Simpson, Andrew E. Pink, Stephan Weidinger, Gary Chan, Pinaki Biswas, Claire Clibborn, Erman Güler

Get full text

In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody by James G. Krueger, Brian S. Kim, Stephan Weidinger, Yoko Kataoka, John T. O'Malley, Karl Yen, Cassie Van Krinks, Jose Vela

Get full text

Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study by Stephan Weidinger, Tobias Schadeck, Felix Jacobs, Ansgar Weyergraf, Dariusch Mortazawi, Tobias Hagemann, Fatima Abousamra, Thomas Mosch, Bjoern Fritz, Felix Lauffer

Get full text

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials by Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger

Get full text

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) by Emma Guttman-Yassky, Stephan Weidinger, Eric L. Simpson, Melinda Gooderham, Alan D. Irvine, Lynda Spelman, Jonathan I. Silverberg, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaçi

Get full text